Belgium-based Celyad SA, which used to go by the name of Cardio3 BioSciences SA, has secured a non-exclusive licensing agreement with Novartis giving the Swiss company rights to US patents for the production of allogeneic CAR T cells. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
